Tarsus Pharmaceuticals Net Profit Margin 2020-2024 | TARS

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Profit Margins Gross Margin Operating Margin EBITDA Margin Pre-Tax Margin Net Margin

Tarsus Pharmaceuticals net profit margin from 2020 to 2024. Net profit margin can be defined as net Income as a portion of total sales revenue.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Profit Margins Gross Margin Operating Margin EBITDA Margin Pre-Tax Margin Net Margin

Tarsus Pharmaceuticals net profit margin from 2020 to 2024. Net profit margin can be defined as net Income as a portion of total sales revenue.

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$145.5B
Vertex Pharmaceuticals (VRTX)	$119.4B
Gilead Sciences (GILD)	$114.5B
Bristol Myers Squibb (BMY)	$113.1B
CSL (CSLLY)	$84.9B
Regeneron Pharmaceuticals (REGN)	$80.4B
GSK (GSK)	$70.4B
Argenex SE (ARGX)	$36.7B
Alnylam Pharmaceuticals (ALNY)	$31.7B
BioNTech SE (BNTX)	$28.6B
Illumina (ILMN)	$22.8B
Biogen (BIIB)	$21.9B
BeiGene (BGNE)	$17.5B
Moderna (MRNA)	$16.1B
Genmab (GMAB)	$13.3B
Incyte (INCY)	$13.2B
Insmed (INSM)	$12.8B
BioMarin Pharmaceutical (BMRN)	$12.6B
Bio-Techne Corp (TECH)	$12B
Sarepta Therapeutics (SRPT)	$11.8B
Exact Sciences (EXAS)	$11.3B
Vaxcyte (PCVX)	$10.9B
QIAGEN (QGEN)	$10.4B
Exelixis (EXEL)	$10B
Bio-Rad Laboratories (BIO.B)	$9.4B
Intra-Cellular Therapies (ITCI)	$8.8B
Repligen (RGEN)	$8.8B
Roivant Sciences (ROIV)	$8.6B
Ascendis Pharma (ASND)	$7.9B
Revolution Medicines (RVMD)	$7.6B